Patel Anish — SEC Form 4 filings
SEC reporting owner CIK 1967163. 26 Form 4 filings on record with FilingPulse; latest filed 2026-02-17.
Transaction summary — filings shown
Covers all 26 filings on record, filed 2024-01-24 to 2026-02-17. Counts and totals are arithmetic on values as filed — descriptive data, not a recommendation.
- Open-market purchases (code P, non-derivative): none reported.
- Open-market sales (code S, non-derivative): 40 legs across 24 filings — 245,091 shares, $5,678,274 total (shares × price as filed).
- Other reported legs (grants, option exercises, tax withholding, gifts, derivative-security transactions, …): 20.
- Largest priced transaction: sale of 48,057 shares @ $27.98 ($1,344,837) in Enliven Therapeutics, Inc., filed 2026-01-13.
By issuer — same filings
Open-market purchase/sale legs on non-derivative securities, grouped by issuer. Role is as filed on the newest filing for that issuer. Dollar totals cover priced legs only (shares × price as filed). Ordered by priced transaction value, largest first.
| Issuer | Role (as filed) | Filings | Purchases (P) | Sales (S) | Other legs |
|---|---|---|---|---|---|
| Enliven Therapeutics, Inc. (ELVN) | CHIEF OPERATING OFFICER | 26 | — | 40 legs · 245,091 sh · $5,678,274 | 20 |
Form 4 filings — Patel Anish
| Filed | Form | Issuer | Reported transactions | Source |
|---|---|---|---|---|
| 2026-02-17 | 4 | Enliven Therapeutics, Inc. (ELVN) | Grant/award (A): 20,000 @ $0 · Grant/award (A): 120,000 (derivative) @ $0 | EDGAR |
| 2026-01-13 | 4 | Enliven Therapeutics, Inc. (ELVN) | Sale (S): 48,057 @ $27.98 · Sale (S): 243 @ $28.50 | EDGAR |
| 2025-12-10 | 4 | Enliven Therapeutics, Inc. (ELVN) | Sale (S): 4,958 @ $20.76 · Sale (S): 1,705 @ $21.78 | EDGAR |
| 2025-11-12 | 4 | Enliven Therapeutics, Inc. (ELVN) | Sale (S): 6,054 @ $17.35 · Sale (S): 613 @ $17.94 | EDGAR |
| 2025-10-09 | 4 | Enliven Therapeutics, Inc. (ELVN) | Sale (S): 6,667 @ $20.10 | EDGAR |
| 2025-09-10 | 4 | Enliven Therapeutics, Inc. (ELVN) | Sale (S): 6,667 @ $20.24 | EDGAR |
| 2025-08-11 | 4 | Enliven Therapeutics, Inc. (ELVN) | Sale (S): 6,262 @ $18.20 · Sale (S): 405 @ $18.93 | EDGAR |
| 2025-07-09 | 4 | Enliven Therapeutics, Inc. (ELVN) | Sale (S): 6,362 @ $19.75 · Sale (S): 305 @ $20.69 | EDGAR |
| 2025-06-11 | 4 | Enliven Therapeutics, Inc. (ELVN) | Sale (S): 6,607 @ $20.33 · Sale (S): 60 @ $21.16 | EDGAR |
| 2025-05-09 | 4 | Enliven Therapeutics, Inc. (ELVN) | Sale (S): 6,173 @ $18.30 · Sale (S): 390 @ $19.40 · Sale (S): 104 @ $19.87 | EDGAR |
| 2025-04-09 | 4 | Enliven Therapeutics, Inc. (ELVN) | Sale (S): 3,756 @ $17.81 · Sale (S): 2,763 @ $18.29 · Sale (S): 148 @ $19.27 | EDGAR |
| 2025-03-11 | 4 | Enliven Therapeutics, Inc. (ELVN) | Sale (S): 6,667 @ $21.44 | EDGAR |
| 2025-02-10 | 4 | Enliven Therapeutics, Inc. (ELVN) | Sale (S): 6,667 @ $21.93 · Grant/award (A): 171,000 (derivative) @ $0 | EDGAR |
| 2025-01-10 | 4 | Enliven Therapeutics, Inc. (ELVN) | Option exercise (M): 10,700 @ $1.12 · Option exercise (M): 2,000 @ $2.48 · Option exercise (M): 9,000 @ $2.48 · Sale (S): 20,260 @ $24.15 · Sale (S): 1,440 @ $24.56 · Sale (S): 6,577 @ $24.17 · +4 more | EDGAR |
| 2024-10-22 | 4 | Enliven Therapeutics, Inc. (ELVN) | Sale (S): 716 @ $30.00 | EDGAR |
| 2024-07-16 | 4 | Enliven Therapeutics, Inc. (ELVN) | Sale (S): 17,475 @ $25.07 · Sale (S): 30,978 @ $25.05 · Sale (S): 1,547 @ $25.01 | EDGAR |
| 2024-06-10 | 4 | Enliven Therapeutics, Inc. (ELVN) | Option exercise (M): 1,133 @ $2.48 · Sale (S): 1,133 @ $20.06 · Option exercise (M): 1,133 (derivative) @ $0 | EDGAR |
| 2024-05-16 | 4 | Enliven Therapeutics, Inc. (ELVN) | Option exercise (M): 1,107 @ $2.48 · Sale (S): 1,107 @ $25 · Option exercise (M): 1,107 (derivative) @ $0 | EDGAR |
| 2024-05-13 | 4 | Enliven Therapeutics, Inc. (ELVN) | Option exercise (M): 260 @ $2.48 · Sale (S): 260 @ $25.06 · Option exercise (M): 260 (derivative) @ $0 | EDGAR |
| 2024-05-08 | 4 | Enliven Therapeutics, Inc. (ELVN) | Option exercise (M): 4,875 @ $2.48 · Sale (S): 4,875 @ $22.72 · Option exercise (M): 4,875 (derivative) @ $0 | EDGAR |
| 2024-04-15 | 4 | Enliven Therapeutics, Inc. (ELVN) | Option exercise (M): 14,903 @ $2.48 · Sale (S): 17,500 @ $25.03 · Option exercise (M): 14,903 (derivative) @ $0 | EDGAR |
| 2024-04-10 | 4 | Enliven Therapeutics, Inc. (ELVN) | Sale (S): 4,331 @ $18.50 · Sale (S): 544 @ $19.40 | EDGAR |
| 2024-03-08 | 4 | Enliven Therapeutics, Inc. (ELVN) | Sale (S): 4,875 @ $15.64 | EDGAR |
| 2024-02-15 | 4 | Enliven Therapeutics, Inc. (ELVN) | Grant/award (A): 185,000 (derivative) @ $0 | EDGAR |
| 2024-02-08 | 4 | Enliven Therapeutics, Inc. (ELVN) | Sale (S): 4,875 @ $15.11 | EDGAR |
| 2024-01-24 | 4 | Enliven Therapeutics, Inc. (ELVN) | Sale (S): 4,875 @ $15.13 | EDGAR |
FilingPulse's Form 4 archive currently extends back to 2024-01-11 and is expanding backward through EDGAR history — earlier filings by this insider may not be indexed yet. Names and roles are shown as filed.
Need this as JSON?
GET https://api.filingpulse.io/v1/insider-trades?owner_cik=1967163 returns every filing on this page — normalized, with footnotes and derivative legs — and webhooks push new filings to you in seconds. API docs →